KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that David Soergel, M.D., its chief medical officer, will present a company overview and update at the 2016 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 23, 2016 at 2:05 p.m. EST in New York.
